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INTRODUCTION  
Candesartan cilexetil 
1
 (CST), 1-[[(cyclohexyloxy) 
carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1H-tetrazo l-5-y l)[1,1'-
biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylate is 
an angiotensin II receptor antagonist, selective for AT1 
receptors, with tight binding to and slow dissociation from 
the receptor (Figure 1). It has no agonist activity. It is 
rapidly converted to the active substance, candesartan, by 
ester hydrolysis during absorption from the gastrointestinal 
tract.  
 
Figure 1: Structure of Candesartan cilexetil (CST) 
Chemically, Hydrochlorothiazide 
2
 (HCT) is 6-chloro-1, 1-
dioxo-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7 
sulfonamide which is a first line diuretic drug of the 
thiazide class (Figure 2). It acts by lowering blood pressure 
initially by increasing sodium and water excretion. Th is 
causes a decrease in extracellu lar volume, resulting in a 
decrease in cardiac output and renal blood flow. W ith 
long-term treatment, plasma volume approaches a normal 
value, but peripheral resistance decreases.
 
 
 
Figure 2: Structure of Hydrochlorothiazide (HCT)  
Literature survey reveals that spectrophotometric 
3
, LC 
4
 
and LC-MS 
5
 methods were developed for the analysis of 
Candesartan cilexetil alone and three HPLC methods were 
proposed for the estimat ion of Hydrochlorothiazide 
6-8
 
alone in bio logical fluids. 
Very few analytical methods such as spectrophotometric 
9
, 
HPLC 
10-12
 and HPTLC 
13
 method have been developed till 
ABSTRACT 
A simple and sensitive RP-HPLC method was developed and validated for the determination of Candesartan 
cilexetil and Hydrochlorthiazide in pharmaceutical dosage forms. The separation of components was achieved on a 
SHIMADZU Hypersil ODS-C18 column (250 × 4.6 mm, 5 µm) with UV detection at 270 nm. Isocratic elution with 
a mobile phase consisting of 10 mM (pH 3.37) Tetra butyl ammonium hydrogen sulphate: methanol (15:85, V/V), at 
a flow rate 1.0 mL min-1 was employed. Linearity was observed in the concentration range 0.625-62.5 µg/mL for 
Hydrochlorthiazide and 0.8-80 µg/mL for Candesartan cilexetil respectively. The linear regression equation was 
found to be Y=64002X-1412.6 for Hydrochlorthiazide and Y=24649X-6701.8 for Candesartan cilexetil respectively 
with correlation coefficients greater than 0.999. The LOD was found to be 0.1385 and 0.1892 µg/mL for 
Hydrochlorthiazide and Candesartan cilexetil respectively where as the LOQ was found to be 0.4394 and 0.6187  
µg/mL for Hydrochlorthiazide and Candesartan cilexetil respectively. The mean analytical recovery in 
determination of Candesartan cilexetil and Hydrochlorthiazide tablets was 99.31-100.08% Hydrochlorthiazide and 
99.58-100.39% for Candesartan cilexetil respectively. Thus, the proposed method is applicable for routine 
determination of Candesartan cilexetil and Hydrochlorthiazide in pharmaceutical formulations.  
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now for the simultaneous determination of Candesartan 
cilexetil and Hydrochlorothiazide in pharmaceutical 
formulat ions and biological fluids. The objective of this 
investigation is to develop an efficient, simple, rapid, 
validated and reliable method for the routine quality 
control analysis for the simultaneous determination of 
Candesartan cilexetil and Hydrochlorthiazide in  
pharmaceutical preparations. 
MATERIALS AND METHODS 
Instrumentation        
A Shimadzu HPLC instrument (LC-10AT Vp) equipped 
with UV-Vis ible detector, manual in jector with 20 µl 
sample loop and A Hibar 250 x 4.6 mm LiChrospher 100 
C18 column (250 mm x 4.6 mm i.d., 5 µm part icle size) 
was used. The output signal was monitored and integrated 
using Shimadzu Class-Vp version 6.12 SP1 software was 
used for separation.  
Reagents and Materials  
Ranbaxy Laboratories Limited, India, kindly gifted 
Candesartan cilexetil and Hydrochlorthiazide pure powder 
with 99.98% and 99.98% purity respectively. HPLC grade 
methanol was purchased from Merck, India.  The water for 
HPLC was obtained from TKA Gen Pure (Pacific) system 
(Germany). Tetra butyl ammonium hydrogen sulphate was 
purchased from S.D. Fine Chemicals, Ahmedabad, India 
and was of analytical grade. CANDELONG-H® 
(Candesartan cilexetil 8 mg and Hydrochlorthiazide 12.5 
mg) and CANDESAR-H® (Candesartan cilexet il 16 mg 
and Hydrochlorthiazide 12.5 mg) brands are available as 
tablet. 
Chromatographic Conditions  
A Shimadzu C18 column (250 mm x 4.6 mm i.d., 5 µm) 
was used at ambient temperature. The mobile phase 
comprised of 0.01 M Tetra butyl ammonium hydrogen 
sulphate (pH 3.37) and methanol (15:85 v/v) was prepared, 
filtered through nylon 0.45 mm membrane filter and 
degassed before use. The mobile phase was pumped at a 
flow rate of 1 mL/min and the elution was monitored at 
270 nm. The injection volume was 20 µL.  
Preparation of Hydrochlorthiazide and Candesartan 
cilexetil Standard Solutions 
Accurately weighed Hydrochlorthiazide (6.25 mg) and 
Candesartan cilexetil (8.0 mg) were transferred to a 100 
mL volumetric flask, dissolved in and diluted to the mark 
with mobile phase to obtain a standard solution having a 
concentration of Hydrochlorthiazide (62.5 µg/mL) and 
Candesartan cilexetil (80 µg/mL). Th is solution was 
further diluted to obtain working standard solutions with 
Hydrochlorthiazide (0.625 -62.5 µg/mL) and Candesartan 
cilexetil (0.8-80 µg/mL) for the HPLC method.  
Preparation of Sample Solutions  
Powder of each of 20 tablets (2 brands, CANDESAR-H® 
and CANDELONG-H®) were weighed and analyzed as 
follows. A mass of tablet powder equivalent to the powder 
of one tablet was weighed from each brand and transferred 
in to a 100 mL volumetric flask separately and methanol 
(80 mL) was added. It was sonicated for 15 minutes and 
final volume was made up to the mark with methanol to 
get a solution with Hydrochlorthiazide (62.5 µg/mL) and 
Candesartan cilexet il (80 µg/mL) for brand I 
(CANDESAR-H®) and Hydrochlorthiazide (62.5 µg/mL) 
and Candesartan cilexetil (40 µg/mL) for brand II 
(CANDELONG-H®). Each mixture was then filtered  
separately through a nylon membrane filter.  
Method Validation 
Specificity (Selectivity) 
The selectivity of the RP HPLC method was checked by 
comparison of chromatograms obtained from samples and 
the corresponding placebo. Additives in tablets are 
sparingly soluble in methanol or the mobile phase, whereas 
the active constituents are freely soluble. 
Linearity 
Calibrat ion curves were constructed by plotting peak areas 
versus concentrations of Hydrochlorthiazide and 
Candesartan cilexetil and the regression equations were 
calculated. A calibration curve was plotted over a 
concentration range 0.625-625 µg/mL for 
Hydrochlorthiazide and 0.8-80 µg/mL for Candesartan 
cilexetil respectively. Accurately measured standard 
working solutions of Hydrochlorthiazide (0.625-62.5 
µg/mL) and Candesartan cilexetil (0.8-80 µg/mL) were 
prepared in a series of 10 mL volumetric flasks and diluted 
to the mark with mobile phase. 20 µL of these solutions 
were injected under operating chromatographic conditions 
at UV detection 270 nm and the peak area was recorded. 
Precision 
The precision was checked by repeatedly (n = 3) inject ing 
standard solutions of three different concentrations  of 
Hydrochlorthiazide (12.5, 25 and 50 µg/mL) and 
Candesartan cilexet il (16, 32 and 64 µg/mL) respectively. 
Intermediate Precision (Reproducibility) 
The intra-day and inter-day precisions of the proposed 
methods were determined by estimating the corresponding 
responses 3 times on the same day and on 3 different days, 
over a period of 1 week, for 3 different concentrations of 
12.5, 25 and 50 µg/mL Hydrochlorthiazide and 16, 32 and 
64 µg/mL for Candesartan cilexetil. The results are 
reported in terms of relative standard deviation.  
The stability of standard solutions can also affect the 
robustness of analytical methods. The stability of the 
standard solutions of the drug substances used in these 
methods was tested over a long period of t ime. One port ion 
of a standard solution was kept at room temperature and 
another portion was stored under refrigeration at 
approximately  48ºC, and the content of these solutions was 
regularly compared with that of a freshly prepared 
solution. 
Accuracy (%  Recovery) 
The accuracy of the methods was determined by 
calculating recoveries of Hydrochlorthiazide and 
Candesartan cilexetil by the standard additions method. 
Known amounts of standard solution of 
Hydrochlorthiazide (0.020, 0.025, 0.030 mg mL
-1
) and 
Candesartan cilexetil (0.0256, 0.032, 0.0384 mg/mL) for 
the HPLC method were added to a pre-quantified sample 
solution of tablet dosage forms (HCT = 0.025 mg/mL and 
CST = 0.032 mg/mL). The amounts of Hydrochlorthiazide  
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and Candesartan cilexetil were estimated by applying these 
values to the regression equation of the calibration curve.  
Limit of Detection and Limit of Quantification  
Experimentally the detection limit is defined as the 
concentration of the analyte producing a signal which is at 
least three times the base line noise measured from peak to 
peak and the quantitation limit  is defined as the 
concentration of the analyte producing the signal which is 
at least ten times the base line noise. The limit of detection 
and the limit of quantification of the drug were calcu lated 
using the following equations as per ICH 
14
 guidelines.
 
LOD = 3.3 × σ / S 
LOQ = 10 × σ  / S 
Where σ = the standard deviation of the response, S = the 
standard deviation of y-intercept of regression lines. 
Analysis of CST and HCT in Combined Tablet Dosage 
Form 
Tablets containing Candesartan cilexet il and 
Hydrochlorthiazide  of the two brands  CANDESAR-H® 
and CANDELONG-H®) were purchased from the local 
market and the drugs were extracted using the mobile 
phase. The response of tablet dosage forms was  measured 
at 270 nm for quantificat ion of Candesartan cilexet il and 
Hydrochlorthiazide respectively as described above. The 
amount of Candesartan cilexet il and Hydrochlorthiazide  
present in sample solutions were determined by fitting the 
responses into the regression equation for Candesartan 
cilexetil and Hydrochlorthiazide.  
 
 
Figure 3: Overlay UV absorption spectrum of Candesartan cilexet il (10 g/ml) and Hydrochlorthiazide (10 g/ml) 
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Figure 4: Representative chromatogram of Candesartan cilexet il (32 µg/mL)  and Hydrochlorthiazide (25 µg/mL) 
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RES ULTS AND DISCUSS ION 
To optimize the HPLC parameters, several mobile phase 
compositions were tried. A satisfactory separation and 
peak symmetry for Candesartan cilexetil and 
Hydrochlorthiazide were obtained with a mobile phase 
mixture consisting of 0.01 M (pH 3.37) Tetra butyl 
ammonium hydrogen Sulphate and methanol (15:85 v/v) to 
get better reproducibility and repeatability. Quantificat ion 
was achieved with UV detection at 270 nm (Figure 3) 
based on peak area. The retention times were 8.100 and 
2.750 mins for Candesartan cilexet il and 
Hydrochlorthiazide respectively. A good resolution of the 
peaks with clear base line separation was found (Figure 4). 
The present proposed method has been compared with the 
previously published liquid chromatographic methods in 
Table 1 
Table 1: Comparison of the performance characteristics of the present liquid chromatographic method with the previous 
published methods 
S. No. Mobile phase / Mode λ (nm) Linearity ( g/mL) Remarks Ref. 
1.  
(0.02 M) potassium 
dihydrogen phosphate: 
methanol: triethylamine  
(25:75:0.2) 
(pH 6.0 ± 0.1) 
 
(Isocratic mode) 
 
 
 
271 
 
 
 
5-45 (HCT) 
 
12-56 (CST) 
 
Narrow range and 
more care for pH 
adjustment & Less 
sensitive 
 
 
 
10 
2 10 mM potassium dihydrogen 
phosphate : methanol : 
acetonitrile (2:80:18, v/v/v) 
(pH 2.5) 
 
((Isocratic mode) 
 
 
 
260 
 
 
0.02-1.0 (HCT) 
 
0.03-2.5 (CST) 
 
 
Very narrow range 
(Biological method) 
 
 
 
11 
3  
Acetonitrile : 0.02M sodium 
acetate 
(Gradient mode) 
 
 
 
265 
 
0.0125-1.25 (HCT) 
 
0.016-0.2 (CST) 
 
 
Very narrow range 
 
 
12 
4  
Methanol:  (10 mM) TBA HS 
(85:15 v/v) 
(Isocratic mode) 
 
 
270 
 
0.625-62.5 (HCT) 
 
0.8-80 (CST) 
Wide linearity range 
and no extra 
reagents for pH 
adjustment 
 
Present 
work 
 
Validation of the Proposed Method 
Specificity (Selectivity) 
The selectivity of the RP-HPLC method was checked by comparison of chromatograms obtained from samples and the 
corresponding placebo. No interference from additives was obtained. 
Linearity 
Linear correlation was obtained in the concentration range of 0.625-62.5 µg/mL for Hydrochlorthiazide and 0.8-80 µg/mL
 
for Candesartan cilexetil (Table 2) respectively. The linear regression equation was found to be Y=64002X-1412.6 for 
Hydrochlorthiazide and Y=24649X-6701.8
 
for Candesartan cilexetil respectively with correlation coefficients  greater than 
0.999 (Figure 5 & 6). 
Table 2: Linearity 
CST  
%  RSD 
HCT  
%  RSD Conc. 
(µg/ml) 
Mean peak area Conc. (µg/ml) Mean peak area 
0.8 19180 ±  44.114 0.23 0.625 44664 ± 169.72 0.38 
1.6 32214 ±164.29 0.51 1.25 71311± 335.16 0.47 
3.2 73947 ± 236.63 0.32 2.5 154098±1232.78 0.80 
4 91489 ± 795.94 0.87 3.125 189825±1366.74 0.72 
8 186392 ± 1211.55 0.65 6.25 389612±1402.60 0.36 
16 396720 ± 2935.73 0.74 12.5 813233± 4228.81 0.52 
32 759988 ± 6763.89 0.89 25 1608031± 11417.02 0.71 
64 1551197 ± 10237.90 0.66 50 3214327± 22178.86 0.69 
80 1988198 ± 15110.31 0.76 62.5 3981171± 25877.61 0.65 
RSD = Relative standard deviation 
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Figure 5: Calibrat ion curve of Candesartan cilexetil 
 
 
Figure 6: Calibrat ion curve of Hydrochlorthiazide 
Precision  
The low % RSD values of inter-day was found to be 0.73-
1.43 and 0.58-1.39 for Candesartan cilexet il and 
Hydrochlorthiazide respectively, while % RSD values of 
intra-day was found to be 0.194-0.564and 0.194–1.003 for 
Candesartan cilexet il and Hydrochlorthiazide respectively. 
The low % RSD values  of intra-day and inter-day 
variations reveal that the proposed methods precise (Table 
3 and 4). 
Table 3: Intra-day and inter-day precision for Candesartan cilexetil (n = 3) 
 
Conc. 
(µg/mL) 
 
 
 
Intra-day precision 
 
Inter-day precision 
Mean area ± SD 
(n = 3) 
RSD (% ) Mean area ± SD 
(n = 3) 
RSD (% ) 
16 397898 ± 771.92 0.194 397729 ± 5687.52 1.43 
32 760893 ± 4291.43 0.564 770981 ± 6322.04 0.82 
64 1562437 ± 4718.56 0.302 1576879 ± 11511.22 0.73 
SD = Standard deviation. RSD = Relative standard deviation 
Table 4: Intra-day and inter-day precision for Hydrochlorthiazide (n = 3) 
 
Conc. 
(µg/mL) 
 
 
 
Intra-day precision 
 
Inter-day precision 
Mean area ± SD (n = 3) RSD (% ) Mean area ± SD (n = 3) RSD (% ) 
12.5 814563 ± 1580.25 0.194 820987 ± 11411.72 1.39 
25 1611251 ± 16160.84 1.003 1723454 ± 10030.50 0.58 
50 3197687 ± 9657.02 0.302 3238768 ± 28177.28 0.87 
SD = Standard deviation. RSD = Relative standard deviation 
Because the stability of standard solutions can also affect 
the robustness of analytical methods, the stability of the 
standard solutions of the drug substances used in these 
methods were tested over a long period of t ime. One 
portion of a standard solution was kept at room 
temperature and the other portion was stored under 
refrigeration at approximately 48C, and the content of 
these solutions was regularly compared with that of a 
freshly prepared solution. No changes in drug 
concentrations were observed for solutions stored under 
refrigeration. But, it is recommended that the standard and 
sample solutions must, therefore, be freshly prepared in  
amber colored flasks to protect from light for both of the 
methods. 
Accuracy 
The recovery experiments were carried out by a standard 
addition method. The percent recoveries obtained were 
99.31-100.08 and 99.58-100.39 for Candesartan cilexetil 
and Hydrochlorthiazide respectively (Table 5). The low 
value of % RSD indicates that the method is accurate. 
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Table 5: Accuracy - Recovery data (n = 3) 
Conc. 
(µg/mL) 
 
Total Conc. 
(µg/mL) 
 
Mean Peak Area  ± SD 
 
%  RSD 
 
Amount recovered  
(%  Recovery)  
Pure drug  
 
Formulation 
HCT CST HCT CST HCT CST HCT CST HCT CST HCT CST 
20 25.6 25 32 45 57.6 2869525.67 
± 16295.38 
1403240.67 
± 4287.59 
0.57 0.31 44.86 
(99.68) 
57.20 
(99.31) 
25 32 25 32 50 64 3211066 ± 
34452.23 
1572033 ± 
3821.73 
1.07 0.24 50.19 
(100.39) 
64.05 
(100.08) 
30 38.4 25 32 55 70.4 3503930.33 
± 34441.49 
1727601.84 
± 19283.27 
0.98 1.12 54.77 
(99.58) 
70.36 
(99.94) 
SD = Standard deviation. RSD = Relative standard deviation 
Limit of Detection and Limit of Quantification 
The LOD was found to be 0.1385 and 0.1892 µg/mL for 
Hydrochlorthiazide and Candesartan cilexet il respectively 
where as the LOQ was found to be 0.4394 and 0.6187 
µg/mL for Hydrochlorthiazide and Candesartan cilexetil 
respectively.  
System suitability  
As system suitability test is an integral part of 
chromatographic methods development and it is used to 
verify that the system is adequate for the analysis to be 
performed, the parameter for Candesartan cilexet il and 
Hydrochlorthiazide was evaluated. The theoretical plates 
were found to be 4723 and 5435 (N >2000) for 
Candesartan cilexetil and Hydrochlorthiazide and the 
resolution was >1.5. The tailing factor was found to be 
1.04 and 1.12) for Candesartan cilexet il and 
Hydrochlorthiazide respectively and the capacity factor 
(k’) was found to be >2.0 fo r both. 
Assay of the Tablet Dosage Forms  
The proposed validated methods were successfully applied 
to determine Candesartan cilexet il and Hydrochlorthiazide  
in their combined tablet dosage form and a model 
chromatogram obtained from the marketed formulat ion 
was shown in Figure 5. The results obtained for 
Candesartan cilexetil and Hydrochlorthiazide was 
comparable with the corresponding labeled amounts 
(Table 6).  
Table 6: Analysis of commercial formulat ion (Tablets)  
 
 
 
 
 
 
CONCLUS ION 
The results of the analysis of pharmaceutical dosage forms 
by the proposed methods are highly reproducible, reliab le, 
and are in good agreement with the label claims of the 
drug. The additives usually present in the pharmaceutical  
formulat ions of the assayed samples did not interfere with 
Candesartan cilexet il and Hydrochlorthiazide. It may be 
said that the proposed methods are precise, sensitive, and 
accurate, so that these can be used as standard 
pharmacopoeial methods for the simultaneous 
determination of Candesartan cilexetil and 
Hydrochlorthiazide in tablets using the HPLC systems. 
The advantages of the proposed method involve a simple 
procedure for sample preparat ion and relatively short time 
of analysis. Apart from th is, it can be used for assays of 
Candesartan cilexetil and Hydrochlorthiazide in biological 
flu ids or in pharmacokinetic investigations. 
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